PMC6129034_01
Treatment lines, durations, and outcomes of Cases 1-3.. Abbreviations: AC-T, doxorubicin-cyclophosphamide and sequential paclitaxel; CEF, cyclophosphamide-epirubicine-5-fluorouracil; CMF, cyclophosphamide-methotrexate-5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease; T-DM1, trastuzumab-emtansine.
ott-11-5459Fig1.jpg
PMC6129034_03_ott-11-5459Fig1.jpg
f1-ott-11-5459
The patient's general condition deteriorated continuously and she died in September 2017 (Figure 1).
PMC6129034_02
Treatment lines, durations, and outcomes of Cases 1-3.. Abbreviations: AC-T, doxorubicin-cyclophosphamide and sequential paclitaxel; CEF, cyclophosphamide-epirubicine-5-fluorouracil; CMF, cyclophosphamide-methotrexate-5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease; T-DM1, trastuzumab-emtansine.
ott-11-5459Fig1.jpg
PMC6129034_03_ott-11-5459Fig1.jpg
f1-ott-11-5459
The patient's general condition deteriorated continuously and she died in September 2017 (Figure 1).
Brain metastases before and 3 months after the introduction of fulvestrant therapy (Case 2).
ott-11-5459Fig2.jpg
PMC6129034_02_ott-11-5459Fig2.jpg
f2-ott-11-5459
During the treatment, the lesions in the brain decreased significantly (Figure 2), and all the other manifestations were stable.
PMC6129034_03
Treatment lines, durations, and outcomes of Cases 1-3.. Abbreviations: AC-T, doxorubicin-cyclophosphamide and sequential paclitaxel; CEF, cyclophosphamide-epirubicine-5-fluorouracil; CMF, cyclophosphamide-methotrexate-5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease; T-DM1, trastuzumab-emtansine.
ott-11-5459Fig1.jpg
PMC6129034_03_ott-11-5459Fig1.jpg
f1-ott-11-5459
The patient's general condition deteriorated continuously and she died in September 2017 (Figure 1).